Topical misoprostol therapy for plasma cell vulvitis: a case series.
OBJECTIVE
To present the first reported case series of plasma cell vulvitis successfully treated with topical misoprostol.


METHODS
Three women with vulvar pain and lesions secondary to plasma cell vulvitis refractory to conventional therapy were treated with topical misoprostol compounded in white petrolatum.


RESULTS
All three patients had resolution of pain and lesions within 6 weeks of starting topical misoprostol. All patients tolerated the 0.01% concentration; however, local side effects were seen with the higher 0.02% concentration.


CONCLUSIONS
Plasma cell vulvitis is a rare and painful vulvar disorder that is often refractory to therapy. All three patients in this case series were successfully treated with topical misoprostol. The immunosuppressive effects of misoprostol are hypothesized to be the mechanisms of action of this novel therapy for plasma cell vulvitis.
Gunter
Jennifer
J
The University of Colorado Health Sciences Center, 4200 East 9th Avenue, Denver, CO 80262, USA. jennifer.gunter@uchsc.edu
Golitz
Loren
L
D000282:Administration, Intravaginal; D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008875:Middle Aged; D016595:Misoprostol / Q000008:administration & dosage*; D010950:Plasma Cells / Q000276:immunology*; D017698:Postmenopause; D016896:Treatment Outcome; D014847:Vulvitis / Q000188:drug therapy* / Q000276:immunology
D007166:Immunosuppressive Agents; D016595:Misoprostol